Updated January 18, 2019 This content is archived.
New research by Steven Lipshultz, MD, A. Conger Goodyear Professor and chair of the Department of Pediatrics, showed that exposure to a common drug for attention deficit hyperactivity disorder isn’t likely to increase cardiovascular risk in healthy children, according to a new study involving primates. “The findings are very reassuring in that even high-dose chronic MPH stimulant therapy did not result in any evidence of abnormal structures or function in the hearts of the monkeys,” he said.